Summary:
- AIM ImmunoTech is facing delisting from the NYSE American due to its low stock price, but plans to appeal.
- Trading will transition to the Pink Open Market starting April 7, 2025.
- Analysts project significant potential upside with price targets far above the current trading value.
AIM ImmunoTech (AIM, Financial) is currently navigating turbulent financial waters as the NYSE American has suspended trading of its common stock and initiated delisting procedures, citing its low market price. Despite this setback, AIM ImmunoTech intends to appeal the decision. In the interim, trading is expected to resume on the Pink Open Market beginning April 7, 2025.
Wall Street Analysts' Target Price Projections
The financial community holds a cautiously optimistic view of AIM ImmunoTech's future. According to projections from two seasoned analysts, the average one-year price target for AIM shares stands at $2.75. This includes a high estimate of $4.50 and a low estimate of $1.00. Notably, the average target suggests a striking upside potential of 2,797.79% from its current valuation of $0.09. For more in-depth analysis, investors can visit the AIM ImmunoTech Inc (AIM, Financial) Forecast page.
Brokerage Firm Recommendations
Brokerage firms have provided their consensus recommendation for AIM ImmunoTech, which currently stands at 2.0 on the rating scale. This implies an "Outperform" status, where a rating of 1 indicates a "Strong Buy" and 5 signals a "Sell". The optimism from analysts reflects a belief in the company's potential, despite the current challenges it faces.
GuruFocus Valuation and Analysis
According to GuruFocus, the estimated GF Value for AIM ImmunoTech in one year's time is pegged at $0.57, suggesting a potential upside of 500.63% from its present price of $0.0949. The GF Value is an indicator of the fair market value based on historical trading multiples, prior business growth, and future performance projections. Investors seeking further information can explore the AIM ImmunoTech Inc (AIM, Financial) Summary page for comprehensive insights.
